Format

Send to

Choose Destination
Allergy. 2014 Jan;69(1):132-5. doi: 10.1111/all.12234. Epub 2013 Oct 10.

Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines.

Author information

1
Department of Dermatology, Allergology and Venerology, University Hospital Schleswig-Holstein, Kiel, Germany.

Abstract

Omalizumab, a monoclonal antibody targeting IgE, is an established therapy for severe allergic asthma and has shown efficacy in chronic spontaneous urticaria. Small-scale studies indicated some beneficial effect also in atopic dermatitis (AD). To evaluate the efficacy of omalizumab in AD and to identify markers associated with treatment response, we conducted a prospective 28-week open-label trial on 20 adults with moderate-to-severe AD. Our results confirm previous observations of a positive response in a subgroup of patients and suggest that responders are characterized by the absence of filaggrin mutations and altered lipid metabolite profiles with high levels of various glycerophospholipids.

KEYWORDS:

anti-IgE; atopic dermatitis; filaggrin; metabolomics; omalizumab

PMID:
24111531
DOI:
10.1111/all.12234
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center